Journal of Rhinology 2012;19(1):8-18.
Published online May 31, 2012.
Update of Sublingual Immunotherapy for Allergic Rhinitis
Ji Eun Lee, Dong Young Kim
1Department of Otorhinolaryngology, Chosun University College of Medicine, Gwangju, Korea.
2Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea. dongkim@snu.ac.kr
알레르기비염 설하면역치료의 최신지견
이지은, 김동영
조선대학교 의과대학 이비인후과학교실,1 서울대학교 의과대학 이비인후과학교실2
Abstract
Current treatment strategies for allergic rhinitis include avoidance of the offending allergens, pharmacotherapy, immunotherapy and surgery. Among them, immunotherapy is the only therapeutic option that modifies the basic allergic mechanism by inducing desensitization and producing a state of anergy in the presence of offending allergens. Immunotherapy by subcutaneous allergen injection (subcutaneous immunotherapy, SCIT) has been used since 1911 and has been demonstrated to be a clinically effective treatment for allergic disorders such as rhinoconjunctivitis and asthma. However, the inconvenience, invasiveness and potentially lethal adverse systemic events associated with SCIT have motivated physicians to develop other routes for the administration of allergens such as orally, sublingually or intranasally. Sublingual immunotherapy (SLIT) has recently received considerable attention around the world as a treatment for allergic rhinitis and is now widely used as an alternative to the subcutaneous route. The Allergic Rhinitis and Its Impact on Asthma (ARIA) group of the WHO has acknowledged the potential effectiveness of SLIT for pollen or mite-sensitized allergic rhinitis. Clinical trials evaluating the efficacy and safety of SLIT have been ongoing worldwide since 1980, and newer studies are evaluating practical applications for improving patient care. SLIT has recently been introduced and become widely available for allergic rhinitis treatment in Korea. We previously published our experiences with SLIT and its use in allergic rhinitis patients sensitized to house dust mites. As evidence continues to accumulate, the validity of SLIT as one of the initial treatment options for allergic rhinitis is now becoming more widely accepted.
Key Words: Allergic Rhinitis;Sublingual Immunotherapy;House Dust Mites




Editorial Office
101 Hyundai ESA Apt., 20, Hyoryeong-ro 77-gil, Seocho-gu, Seoul 06628, Republic of Korea
Tel: +82-2-3461-9945    Fax: +82-2-3461-9947    E-mail: shcho@hanyang.ac.kr                

Copyright © 2020 by Korean Rhinologic Society. All rights reserved.

Close layer
prev next